Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BONNASDAQ:IRONNASDAQ:JAN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBONBon Natural Life$0.06+22.5%$0.16$0.05▼$3.35$266K-0.4711.27 million shs297.25 million shsIRONDisc Medicine$48.09+2.1%$46.10$30.65▼$68.73$1.66B0.77349,983 shs442,342 shsJANJanOne$2.57$0.22▼$5.26$20.03M2.16229,417 shs139,500 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBONBon Natural Life0.00%+16.21%+11.15%-95.17%-97.48%IRONDisc Medicine0.00%+8.70%+14.04%-11.11%+50.94%JANJanOne0.00%0.00%0.00%0.00%-34.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBONBon Natural LifeN/AN/AN/AN/AN/AN/AN/AN/AIRONDisc Medicine2.891 of 5 stars4.51.00.00.03.02.50.0JANJanOneN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBONBon Natural Life 0.00N/AN/AN/AIRONDisc Medicine 3.09Buy$98.80105.45% UpsideJANJanOne 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IRON, BON, BSFA, and JAN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025IRONDisc MedicineBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $120.003/18/2025IRONDisc MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$99.00 ➝ $132.003/7/2025IRONDisc MedicineMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$85.003/3/2025IRONDisc MedicineScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$73.00 ➝ $75.002/27/2025IRONDisc MedicineTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBONBon Natural Life$23.84M0.01$0.08 per share0.78$37.78 per share0.00IRONDisc MedicineN/AN/AN/AN/A$14.17 per shareN/AJANJanOne$39.61M0.00N/AN/A($0.67) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBONBon Natural Life$400KN/A0.00∞N/AN/AN/AN/AN/AIRONDisc Medicine-$76.43M-$3.92N/AN/AN/AN/A-25.24%-23.96%N/AJANJanOne-$7.81MN/A0.00N/AN/AN/A-359.71%-70.26%N/ALatest IRON, BON, BSFA, and JAN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025IRONDisc Medicine-$0.99-$1.02-$0.03-$1.02N/AN/A2/27/2025Q4 2024IRONDisc Medicine-$1.06-$0.98+$0.08-$0.98N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBONBon Natural LifeN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/AJANJanOneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBONBon Natural Life0.022.422.32IRONDisc MedicineN/A19.3619.36JANJanOneN/A0.150.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBONBon Natural Life0.57%IRONDisc Medicine83.70%JANJanOne6.27%Insider OwnershipCompanyInsider OwnershipBONBon Natural Life26.48%IRONDisc Medicine4.24%JANJanOne3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBONBon Natural Life1004.17 million863,000Not OptionableIRONDisc Medicine3034.57 million28.50 millionNot OptionableJANJanOne1708.98 million8.71 millionNot OptionableIRON, BON, BSFA, and JAN HeadlinesRecent News About These CompaniesBiotech Company Loses Insurance Appeal on SEC Probe ExpensesMay 9, 2025 | news.bloomberglaw.comAppeals Court Grills Biotech, Insurer on SEC Probe CoverageApril 9, 2025 | news.bloomberglaw.comNew Dayton-based publicly traded company in the works with prominent local leaderOctober 7, 2024 | bizjournals.comL-L League field hockey capsules: Who's who in Section 2 for 2024August 27, 2024 | lancasteronline.comJANONE CONFIRMS NAME CHANGE TO ALT5 SIGMA CORPORATION AND NEW TICKER SYMBOL TO ALTSJuly 12, 2024 | prnewswire.comJanOne Announces Plan to Enhance Stockholder Value Through Strategic RealignmentJuly 10, 2024 | prnewswire.com3 Fintech Stocks to Sell in July Before They Crash & BurnJuly 8, 2024 | investorplace.comJanOne Appoints Vay Tham as its Chief Revenue Officer and President of its Fintech Subsidiary, ALT5 SigmaJune 26, 2024 | prnewswire.comALT5 SIGMA, A JANONE COMPANY, ADDS PREPAID VISA®️ CARD INTEGRATION TO ALT5 SETTLEMENT PLATFORMJune 25, 2024 | prnewswire.comJanOne's Subsidiary, Alt5, Reports 91% year over year increase in Transaction Volume to US $289 million for April and May 2024June 13, 2024 | prnewswire.comALT5 Sigma, a wholly-owned subsidiary of JanOne, Launches ALT5 Settlement Platform aimed at the untapped $27.3 Billion Global Digital Content Creation MarketJune 11, 2024 | prnewswire.comJanOne Inc. added to the Russell Microcap® IndexJune 3, 2024 | prnewswire.comALT 5 Sigma, a wholly-owned subsidiary of JanOne to Present at the iFX Expo, the World's largest online trading conference and tradeshowMay 28, 2024 | prnewswire.comIt’s not the right time to quit: JanOne Inc (JAN) StockMay 27, 2024 | bovnews.comJanOne Inc. (JAN) Stock Price, News, Quote & History - Yahoo FinanceMay 16, 2024 | finance.yahoo.comJanOne Closes Acquisition of ALT 5 Sigma Inc., a Leading Next Generation Blockchain FintechMay 16, 2024 | prnewswire.comWhy Tevogen Bio Holdings Stock Is Moving Higher TodayMay 13, 2024 | msn.comJanOne To Buy Block Chain Fintech Provider ALT 5 Sigma In All-stock Deal; JAN Up In Pre-marketMay 13, 2024 | markets.businessinsider.comJanone To Acquire Blockchain Fintech Provider ALT 5 SigmaMay 12, 2024 | crowdfundinsider.comIs JanOne Inc (JAN) Stock worth its current valuation?May 11, 2024 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesMedtronic: A Dividend Aristocrat With Stability and InnovationBy Jeffrey Neal Johnson | April 22, 2025View Medtronic: A Dividend Aristocrat With Stability and Innovation3 ETFs Beating the S&P 500 as Volatility RisesBy Gabriel Osorio-Mazilli | May 12, 2025View 3 ETFs Beating the S&P 500 as Volatility RisesBuild a Complete Bond Portfolio With These 4 ETFsBy Nathan Reiff | May 17, 2025View Build a Complete Bond Portfolio With These 4 ETFsIs It Time to Load Up on Bond ETFs?By Nathan Reiff | May 2, 2025View Is It Time to Load Up on Bond ETFs?Steepening Yield Curve? These 3 Bank Stocks Are Poised to ProfitBy Gabriel Osorio-Mazilli | May 15, 2025View Steepening Yield Curve? These 3 Bank Stocks Are Poised to ProfitIRON, BON, BSFA, and JAN Company DescriptionsBon Natural Life NYSE:BON$0.06 +0.01 (+22.46%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$0.05 -0.01 (-18.65%) As of 05/16/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. It offers personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; and natural health supplements comprising powder drinks and bioactive food ingredient products used as food additives and nutritional supplements. Its products are used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is based in Xi'an, the People's Republic of China.Disc Medicine NASDAQ:IRON$48.09 +1.00 (+2.12%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$47.00 -1.09 (-2.27%) As of 05/16/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.JanOne NASDAQ:JANJanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
